Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...
TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with Gardasil’s challenges in China. It is ...
Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms that no legally binding agreement has been ...
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...
Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb ...
Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...
Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...
On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...
Investing.com -- Merck &Company Inc (NYSE:MRK) shares tumbled more than 10% Tuesday after reporting mixed fourth-quarter results, with earnings falling short of expectations, revenue surpassing ...
For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per ...
Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...